{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015733","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.695142+00:00","generated_at":"2026-06-15T22:47:38.183996+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell Immunopharma Q1 net loss $67M; cash $668M; two Phase 1 trials ongoing","bullets":["GAAP net loss of $67.0M for Q1 2023, compared to $68.1M in Q1 2022; non-GAAP net loss $44.8M vs $50.0M.","Cash, equivalents and marketable securities of $668.0M as of March 31, 2023; cash runway into 2026.","Revenue $0.1M, down from $0.6M due to termination of GSK collaboration in December 2022.","Two Phase 1 trials (LYL797 CAR-T and LYL845 TIL) recruiting at 14 US sites; initial clinical data expected in 2024.","LYL119 IND submission expected in first half of 2024; abstract at ASGCT May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015733","json":"https://secwatch.observer/filing/0001628280-23-015733.json","markdown":"https://secwatch.observer/filing/0001628280-23-015733.md","text":"https://secwatch.observer/filing/0001628280-23-015733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/0001628280-23-015733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/lyel-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:47:38.183996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29444f6c0f744effafd64c4a781f1b54eb82561a","claim":"Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.1 million, net income $67.0 million net loss.","evidence_excerpt":"First Quarter Financial Results Lyell reported a net loss of $67.0 million for the first quarter ended March 31, 2023, compared to a net loss of $68.1 million for the same period in 2022. Non‐GAAP net loss, which excludes non-cash stock-based compensation, non‐cash expenses related to the change in the estimated fair value of success payment liabilities and certain non-cash investment gains and charges, was $44.8 million for the first quarter ended March 31, 2023, compared to $50.0 million for the same period in 2022. Revenue • Revenue was $0.1 million for the first quarter ended March 31, 2023 compared to $0.6 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/0001628280-23-015733-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"$67.0 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}